{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:36:50Z","timestamp":1789655810054,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG062706"],"award-info":[{"award-number":["R01AG062706"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Positron emission tomography (PET) is the current gold standard for assessing amyloid burden in vivo and is often quantified using standardized uptake value ratios (SUVRs). We evaluated the performance of four SUVR calculation methods for predicting amyloid deposition at autopsy in a group of oldest-old participants. We analyzed data from 165 participants from\n                    <jats:italic>The 90\u2009+\u2009Study<\/jats:italic>\n                    with both florbetapir PET and postmortem assessments. PET scans were re-aligned to an older age template using a custom MRI-free pipeline. SUVRs were computed from two target regions\u2014combined posterior cingulate and precuneus (PC\n                    <jats:sup>2<\/jats:sup>\n                    ) and an established cortical summary region\u2014and two reference regions\u2014white matter (WM) and cerebellar gray matter. Their predictive performance for amyloid beta positivity (Thal phase\u2009\u2265\u20093) and neuritic plaque positivity (moderate or frequent CERAD score) was evaluated using receiver operating characteristic analyses, including DeLong\u2019s test for comparisons. Participants had a mean (\u00b1\u2009standard deviation) age at PET of 94\u2009\u00b1\u20093 years, and age at death of 97\u2009\u00b1\u20094 years. Most participants had amyloid at autopsy: 113 (68%) were amyloid beta positive, and 104 (63%) were neuritic plaque positive. The best performing SUVR was the PC\n                    <jats:sup>2<\/jats:sup>\n                    +WM, yielding an area under the curve (AUC) of 0.84 (95% CI 0.78\u20130.90) for amyloid beta and 0.82 (95% CI 0.76\u20130.89) for neuritic plaque, with an optimal cutoff of 0.77 for both outcomes. Reference and target region selection was more consequential for predicting amyloid beta positivity, with the WM consistently outperforming the cerebellar gray matter as a reference region for both target regions, while the PC\n                    <jats:sup>2<\/jats:sup>\n                    significantly outperformed the cortical summary region for the cerebellar gray matter reference (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) but only trended for significance for the WM reference (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.069, DeLong\u2019s test). Our findings suggest that using a WM reference and a limited cortical target region may improve PET-neuropathology correspondence, especially in older cohorts.\n                  <\/jats:p>","DOI":"10.1186\/s40478-025-02198-3","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T18:36:46Z","timestamp":1764614206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amyloid quantification in the oldest-old: selecting regions for optimizing correspondence between postmortem pathology and amyloid PET"],"prefix":"10.1186","volume":"14","author":[{"given":"Jiaxin","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis C.","family":"Woodworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Greenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Montine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Corrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia H.","family":"Kawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"DeCarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ahmad","family":"Sajjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2198_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement J Alzheimers Assoc 20:5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR3","doi-asserted-by":"publisher","first-page":"e14342","DOI":"10.1002\/alz.14342","volume":"21","author":"P Aisen","year":"2025","unstructured":"Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T et al (2025) The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer\u2019s disease based on clearcut biomarker evidence. Alzheimers Dement J Alzheimers Assoc 21:e14342. https:\/\/doi.org\/10.1002\/alz.14342","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease. Neurology 34:939\u2013944. https:\/\/doi.org\/10.1212\/wnl.34.7.939","journal-title":"Neurology"},{"key":"2198_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305:275\u2013283. https:\/\/doi.org\/10.1001\/jama.2010.2008","journal-title":"JAMA"},{"key":"2198_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2967\/jnumed.110.076315","volume":"41","author":"CC Rowe","year":"2013","unstructured":"Rowe CC, Villemagne VL (2013) Brain amyloid imaging. J Nucl Med Technol 41:11\u201318. https:\/\/doi.org\/10.2967\/jnumed.110.076315","journal-title":"J Nucl Med Technol"},{"key":"2198_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.118.209130","volume":"60","author":"P Chiao","year":"2019","unstructured":"Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand\u2019Maison M, O\u2019Neill P et al (2019) Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab. J Nucl Med Off Publ Soc Nucl Med 60:100\u2013106. https:\/\/doi.org\/10.2967\/jnumed.118.209130","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"2198_CR8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N et al (2011) Using positron emission tomography and Florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68:1404\u20131411. https:\/\/doi.org\/10.1001\/archneurol.2011.150","journal-title":"Arch Neurol"},{"key":"2198_CR9","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s00259-017-3666-8","volume":"44","author":"J Blautzik","year":"2017","unstructured":"Blautzik J, Brendel M, Sauerbeck J, Kotz S, Scheiwein F, Bartenstein P et al (2017) Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden. Eur J Nucl Med Mol Imaging 44:1364\u20131374. https:\/\/doi.org\/10.1007\/s00259-017-3666-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2198_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jalz.2014.09.004","volume":"11","author":"ME Schmidt","year":"2015","unstructured":"Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE et al (2015) The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement J Alzheimers Assoc 11:1050\u20131068. https:\/\/doi.org\/10.1016\/j.jalz.2014.09.004","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger T, Devous MD, Jagust W et al (2015) The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement J Alzheimers Assoc 11:1\u201315e4. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR12","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE et al (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9:S72\u201383. https:\/\/doi.org\/10.1016\/j.jalz.2012.10.007","journal-title":"Alzheimers Dement"},{"key":"2198_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K et al (2015) Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med Off Publ Soc Nucl Med 56:567\u2013574. https:\/\/doi.org\/10.2967\/jnumed.114.148981","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"2198_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jalz.2017.02.009","volume":"13","author":"AS Fleisher","year":"2017","unstructured":"Fleisher AS, Joshi AD, Sundell KL, Chen Y-F, Kollack-Walker S, Lu M et al (2017) Use of white matter reference regions for detection of change in Florbetapir positron emission tomography from completed phase 3 Solanezumab trials. Alzheimers Dement J Alzheimers Assoc 13:1117\u20131124. https:\/\/doi.org\/10.1016\/j.jalz.2017.02.009","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N et al (2015) Improved power for characterizing longitudinal amyloid-\u03b2 PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med Off Publ Soc Nucl Med 56:560\u2013566. https:\/\/doi.org\/10.2967\/jnumed.114.149732","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"2198_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/01.CON.0000429172.27815.3f","volume":"19","author":"SS Bullain","year":"2013","unstructured":"Bullain SS, Corrada MM (2013) Dementia in the oldest old. Contin Minneap Minn 19:457\u2013469. https:\/\/doi.org\/10.1212\/01.CON.0000429172.27815.3f","journal-title":"Contin Minneap Minn"},{"key":"2198_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2174\/156720506779025233","volume":"3","author":"CH Kawas","year":"2006","unstructured":"Kawas CH, Corrada MM (2006) Alzheimer\u2019s and dementia in the oldest-old: a century of challenges. Curr Alzheimer Res 3:411\u2013419. https:\/\/doi.org\/10.2174\/156720506779025233","journal-title":"Curr Alzheimer Res"},{"key":"2198_CR18","doi-asserted-by":"publisher","first-page":"9068","DOI":"10.1002\/alz.14357","volume":"20","author":"S Dutt","year":"2024","unstructured":"Dutt S, Woodworth DC, Sajjadi SA, Greenia DE, DeCarli C, Kawas CH et al (2024) Cerebral perfusion and amyloidosis in the oldest-old. Alzheimers Dement 20:9068\u20139075. https:\/\/doi.org\/10.1002\/alz.14357","journal-title":"Alzheimers Dement"},{"key":"2198_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JAD-201578","volume":"82","author":"DC Woodworth","year":"2021","unstructured":"Woodworth DC, Scambray KA, Corrada MM, Kawas CH, Sajjadi SA (2021) Neuroimaging in the oldest-old: a review of the literature. J Alzheimers Dis JAD 82:129\u2013147. https:\/\/doi.org\/10.3233\/JAD-201578","journal-title":"J Alzheimers Dis JAD"},{"key":"2198_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1212\/WNL.0000000000000977","volume":"83","author":"OL Lopez","year":"2014","unstructured":"Lopez OL, Klunk WE, Mathis C, Coleman RL, Price J, Becker JT et al (2014) Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology 83:1804\u20131811. https:\/\/doi.org\/10.1212\/WNL.0000000000000977","journal-title":"Neurology"},{"key":"2198_CR21","doi-asserted-by":"publisher","first-page":"e209665","DOI":"10.1212\/WNL.0000000000209665","volume":"103","author":"J Wang","year":"2024","unstructured":"Wang J, Ackley S, Woodworth DC, Sajjadi SA, Decarli CS, Fletcher EF et al (2024) Associations of amyloid burden, white matter hyperintensities, and hippocampal volume with cognitive trajectories in the 90\u2009+\u2009study. Neurology 103:e209665. https:\/\/doi.org\/10.1212\/WNL.0000000000209665","journal-title":"Neurology"},{"key":"2198_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1212\/WNL.0000000000001831","volume":"85","author":"CH Kawas","year":"2015","unstructured":"Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM (2015) Multiple pathologies are common and related to dementia in the oldest-old. Neurology 85:535\u2013542. https:\/\/doi.org\/10.1212\/WNL.0000000000001831","journal-title":"Neurology"},{"key":"2198_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/alzrt181","volume":"5","author":"RC Gardner","year":"2013","unstructured":"Gardner RC, Valcour V, Yaffe K (2013) Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimers Res Ther 5:27. https:\/\/doi.org\/10.1186\/alzrt181","journal-title":"Alzheimers Res Ther"},{"key":"2198_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ana.21915","volume":"67","author":"MM Corrada","year":"2010","unstructured":"Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH (2010) Dementia incidence continues to increase with age in the oldest old: the 90\u2009+\u2009study. Ann Neurol 67:114\u2013121. https:\/\/doi.org\/10.1002\/ana.21915","journal-title":"Ann Neurol"},{"key":"2198_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/0021-9681(86)90153-0","volume":"39","author":"A Paganini-Hill","year":"1986","unstructured":"Paganini-Hill A, Ross RK, Henderson BE (1986) Prevalence of chronic disease and health practices in a retirement community. J Chronic Dis 39:699\u2013707. https:\/\/doi.org\/10.1016\/0021-9681(86)90153-0","journal-title":"J Chronic Dis"},{"key":"2198_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/WAD.0000000000000260","volume":"33","author":"ZA Melikyan","year":"2019","unstructured":"Melikyan ZA, Greenia DE, Corrada-Bravo MM, Hester MM, Kawas CH, Grill JD (2019) Recruiting the oldest-old for clinical research. Alzheimer Dis Assoc Disord 33:160\u2013162. https:\/\/doi.org\/10.1097\/WAD.0000000000000260","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2198_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/alz.12668","volume":"19","author":"SM Landau","year":"2023","unstructured":"Landau SM, Ward TJ, Murphy A, Iaccarino L, Harrison TM, La Joie R et al (2023) Quantification of amyloid beta and Tau PET without a structural MRI. Alzheimers Dement J Alzheimers Assoc 19:444\u2013455. https:\/\/doi.org\/10.1002\/alz.12668","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2198_CR28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jalz.2019.06.3464","volume":"15","author":"SA Sajjadi","year":"2019","unstructured":"Sajjadi SA, Fletcher E, Sheikh-Bahaei N, Greenia D, Woodworth D, Singh B et al (2019) P3-430: the relation between amyloid imaging and amyloid pathology in the oldest old: the 90\u2009+\u2009study Alzheimers Dement 15:1124\u20131125","journal-title":"Alzheimers Dement"},{"key":"2198_CR29","unstructured":"Landau S, Murphy A, Ward T, Jagust W (2021) Florbetapir (AV45) processing methods"},{"key":"2198_CR30","doi-asserted-by":"publisher","first-page":"e1005350","DOI":"10.1371\/journal.pcbi.1005350","volume":"13","author":"A Klein","year":"2017","unstructured":"Klein A, Ghosh SS, Bao FS, Giard J, H\u00e4me Y, Stavsky E et al (2017) Mindboggling morphometry of human brains. PLOS Comput Biol Public Libr Sci 13:e1005350. https:\/\/doi.org\/10.1371\/journal.pcbi.1005350","journal-title":"PLOS Comput Biol Public Libr Sci"},{"key":"2198_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol (Berl) 123:1\u201311. https:\/\/doi.org\/10.1007\/s00401-011-0910-3","journal-title":"Acta Neuropathol (Berl)"},{"key":"2198_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/jnen\/59.8.733","volume":"59","author":"DR Thal","year":"2000","unstructured":"Thal DR, R\u00fcb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K et al (2000) Sequence of Abeta-protein deposition in the human medial Temporal lobe. J Neuropathol Exp Neurol 59:733\u2013748. https:\/\/doi.org\/10.1093\/jnen\/59.8.733","journal-title":"J Neuropathol Exp Neurol"},{"key":"2198_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging\u2013Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8:1\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.007","journal-title":"Alzheimers Dement"},{"key":"2198_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/wnl.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The consortium to Establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41:479\u2013486. https:\/\/doi.org\/10.1212\/wnl.41.4.479","journal-title":"Neurology"},{"key":"2198_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C et al (2011) pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics 12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77","journal-title":"BMC Bioinformatics"},{"key":"2198_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2307\/2331986","volume":"26","author":"CJ Clopper","year":"1937","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. [Oxford University Press, Biometrika Trust] 26:404\u2013413. https:\/\/doi.org\/10.2307\/2331986","journal-title":"Biometrika. [Oxford University Press, Biometrika Trust]"},{"key":"2198_CR37","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1212\/01.wnl.0000240117.55680.0a","volume":"67","author":"NM Kemppainen","year":"2006","unstructured":"Kemppainen NM, Aalto S, Wilson IA, N\u00e5gren K, Helin S, Br\u00fcck A et al (2006) Voxel-based analysis of PET amyloid ligand [11\u00a0C]PIB uptake in Alzheimer disease. Neurology 67:1575\u20131580. https:\/\/doi.org\/10.1212\/01.wnl.0000240117.55680.0a","journal-title":"Neurology"},{"key":"2198_CR38","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146:4414\u20134424. https:\/\/doi.org\/10.1093\/brain\/awad188","journal-title":"Brain"},{"key":"2198_CR39","doi-asserted-by":"publisher","first-page":"e230009","DOI":"10.1148\/rg.230009","volume":"43","author":"A Agarwal","year":"2023","unstructured":"Agarwal A, Gupta V, Brahmbhatt P, Desai A, Vibhute P, Joseph-Mathurin N et al (2023) Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-\u03b2 therapy. RadioGraphics Radiological Soc North Am 43:e230009. https:\/\/doi.org\/10.1148\/rg.230009","journal-title":"RadioGraphics Radiological Soc North Am"},{"key":"2198_CR40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jnnp-2024-333468","volume":"95","author":"R Dobson","year":"2024","unstructured":"Dobson R, Patterson K, Malik R, Mandal U, Asif H, Humphreys R et al (2024) Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 95:796\u2013803. https:\/\/doi.org\/10.1136\/jnnp-2024-333468","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2198_CR41","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1002\/alz.14108","volume":"20","author":"S Walsh","year":"2024","unstructured":"Walsh S, Merrick R, Milne R, Nurock S, Richard E, Brayne C (2024) Considering challenges for the new Alzheimer\u2019s drugs: clinical, population, and health system perspectives. Alzheimers Dement 20:6639\u20136646. https:\/\/doi.org\/10.1002\/alz.14108","journal-title":"Alzheimers Dement"},{"key":"2198_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.nicl.2016.11.008","volume":"13","author":"SW Seo","year":"2017","unstructured":"Seo SW, Ayakta N, Grinberg LT, Villeneuve S, Lehmann M, Reed B et al (2017) Regional correlations between [11\u00a0C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage Clin 13:130\u2013137. https:\/\/doi.org\/10.1016\/j.nicl.2016.11.008","journal-title":"NeuroImage Clin"},{"key":"2198_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al (2012) Cerebral PET with Florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol 11:669\u2013678. https:\/\/doi.org\/10.1016\/S1474-4422(12)70142-4","journal-title":"Lancet Neurol"},{"key":"2198_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN et al (2015) Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 72:287\u2013294. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4144","journal-title":"JAMA Neurol"},{"key":"2198_CR45","doi-asserted-by":"publisher","first-page":"748198","DOI":"10.3389\/fnagi.2021.748198","volume":"13","author":"SJ Teipel","year":"2021","unstructured":"Teipel SJ, Dyrba M, Vergallo A, Lista S, Habert MO, Potier M-C et al (2021) Partial volume correction increases the sensitivity of 18F-Florbetapir-Positron emission tomography for the detection of early stage amyloidosis. Front Aging Neurosci 13:748198. https:\/\/doi.org\/10.3389\/fnagi.2021.748198","journal-title":"Front Aging Neurosci"},{"key":"2198_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neuroimage.2014.11.058","volume":"107","author":"Y Su","year":"2015","unstructured":"Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM et al (2015) Partial volume correction in quantitative amyloid imaging. NeuroImage 107:55\u201364. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.11.058","journal-title":"NeuroImage"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02198-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02198-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02198-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:52:04Z","timestamp":1781621524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-025-02198-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2198"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02198-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants or their designated surrogates provided consent to participate in the study. Procedures were reviewed and approved by the Institutional Review Board at the University of California, Irvine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}